FOLD has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
FOLD has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Amicus Therapeutics's earnings per share without non-recurring items for the three months ended in Dec. 2024 was $0.09. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was $0.23.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Amicus Therapeutics's EPS without NRI or its related term are showing as below:
During the past 13 years, Amicus Therapeutics's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 86.30% per year. The lowest was -68.60% per year. And the median was 10.00% per year.
Amicus Therapeutics's EPS (Diluted) for the three months ended in Dec. 2024 was $0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.18.
Amicus Therapeutics's EPS (Basic) for the three months ended in Dec. 2024 was $0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $-0.18.
The historical data trend for Amicus Therapeutics's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amicus Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | Dec24 | |||||||||||
EPS without NRI | Get a 7-Day Free Trial |
![]() |
![]() |
-1.03 | -0.90 | -0.79 | -0.46 | 0.24 |
Amicus Therapeutics Quarterly Data | ||||||||||||||||||||
Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | Dec24 | |
EPS without NRI | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
-0.07 | -0.02 | 0.06 | 0.10 | 0.09 |
For the Biotechnology subindustry, Amicus Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Amicus Therapeutics's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.23
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amicus Therapeutics (NAS:FOLD) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Amicus Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.
Bradley L Campbell | director, officer: President and CEO | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Margaret G Mcglynn | director | C/O MERCK & CO INC, ONE MERCK DRIVE PO BOX 100, WHITEHOUSE STATION NJ 08889-0100 |
John F Crowley | director, officer: Executive Chairman | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
David Michael Clark | officer: Chief People Officer | 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Ellen Rosenberg | officer: General Counsel & Corp. Secy | C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08560 |
Samantha Prout | officer: Principal Accounting Officer | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Jeff Castelli | officer: VP, Program Management | 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Harford Simon N.r. | officer: Chief Financial Officer | AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105 |
Michael Raab | director | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
Daphne Quimi | officer: Chief Financial Officer | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Burke W Whitman | director | 13455 NOEL ROAD # 2000, DALLAS TX 75240 |
Eiry Roberts | director | C/O NEUROCRINE BIOSCIENCES, INC., 12780 EL CAMINO REAL, SAN DIEO CA 92130 |
Hung Do | officer: Sr Vice President Discovery | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Michael Aaron Kelly | director | C/O HOOKIPA PHARMA INC., 430 EAST 29TH ST., NEW YORK NY 10016 |
Jay Barth | officer: Chief Medical Officer | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
From GuruFocus
By GuruFocus News • 01-02-2025
By GuruFocus News • 11-14-2024
By GlobeNewswire • 01-12-2025
By GuruFocus News • 02-10-2025
By GuruFocus News • 11-14-2024
By GuruFocus News • 02-15-2025
By GuruFocus News • 11-07-2024
By GuruFocus News • 02-20-2025
By Marketwired • 02-19-2025
By GuruFocus News • 02-19-2025
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.